Key result
No clinical study data is present in the provided text, which consists only of a journal masthead.
Why the study?
Can the platelet function analyzer PFA-100 reliably identify nonresponders to acetylsalicylic acid therapy in patients with atherosclerosis?
Population
Patients with atherosclerosis or atherothrombosis receiving acetylsalicylic acid (ASA) therapy
Design
Review
Authors
Loading...
No study data available precludes practice change; leaves open utility of PFA-100 for acetylsalicylic acid nonresponse monitoring.
Can the platelet function analyzer PFA-100 reliably identify nonresponders to acetylsalicylic acid therapy in patients with atherosclerosis?
The PFA-100 device shows potential for routine clinical use in identifying patients who do not respond adequately to aspirin therapy, allowing for tailored antiplatelet strategies.
Feuring et al. (2005) studied this question. No clinical study data is present in the provided text, which consists only of a journal masthead.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: